• Salman Nusrat and Philip B Miner.
• a Section of Digestive Diseases and Nutrition, Department of Medicine , Oklahoma University School of Medicine , 920 Stanton L. Young Blvd. WP 1345, Oklahoma City , OK 73104 , USA.
• Expert Opin Emerg Drugs. 2015 Jan 1; 20 (4): 625-36.

IntroductionConstipation predominant irritable bowel syndrome (IBS-C) is a common disorder and accounts for a large number of ambulatory visits. Sensory abnormalities, that is, presence of abdominal pain and discomfort, distinguish IBS-C from chronic idiopathic constipation.Area CoveredThis review focuses on the pharmacology, efficacy, safety, and future of prucalopride, YKP-10811, DSP-6952, dexloxiglumide, linaclotide, plecanatide, tenapanor, and elobixibat.Expert OpinionIt is now well established that treatment focusing only on bowel transit provides incomplete relief to patients with IBS-C. Improved understanding of pathophysiology of IBS-C has led to use of sensory end points like complete spontaneous bowel movements and the FDA combined end point (abdominal pain and complete spontaneous bowel movements) in clinical trials. A number of drugs are in development and provide hope for this challenging group of patients. However, because of recent failures secondary to ineffectiveness and/or adverse events, we cautiously await how clinical data play out in larger studies and in clinical practice.

18 keywords...

hide…